Management of Mitral Valve Prolapse Symptoms

Assessment and Classification

The American College of Cardiology recommends that mitral valve prolapse (MVP) be classified based on severity: Stage A (mild MVP with normal coaptation and no MR), Stage B (progressive MVP with mild-to-moderate MR), Stage C (severe MVP with loss of coaptation or flail leaflet and severe MR), and Stage D (symptomatic severe MVP with severe MR) 2
Echocardiography is essential for diagnosis, assessing valve morphology, determining MR severity, and evaluating left ventricular size and function, as recommended by the American Heart Association 3, 1
Quantitative parameters should be used to assess MR severity, with severe primary MR defined as effective regurgitant orifice area ≥0.4 cm² and regurgitant volume ≥60 mL, according to the American College of Cardiology 1

Asymptomatic patients with moderate MR should have clinical follow-up every 6 months with annual echocardiography, as recommended by the American College of Cardiology 1
Surgery should be considered in asymptomatic patients with severe MR if any of the following are present: left ventricular dysfunction (LVEF ≤60% or LVESD ≥40 mm), new onset atrial fibrillation, or pulmonary hypertension, according to the American Heart Association 4, 1
Mitral valve surgery is strongly recommended for symptomatic patients with chronic severe primary MR (stage D) and LVEF greater than 30%, as recommended by the American College of Cardiology 4, 1

There is no evidence supporting the use of vasodilators, including ACE inhibitors, in chronic MR without heart failure, according to the American College of Cardiology 1
ACE inhibitors should be used in patients with advanced MR and severe symptoms who are not surgical candidates, as recommended by the American Heart Association 1
For patients with MVP and atrial fibrillation, anticoagulation therapy is recommended based on age and risk factors, with Warfarin therapy recommended for patients aged >65 or those with hypertension, MR murmur, or history of heart failure, and Aspirin therapy recommended for patients <65 years without MR, hypertension, or heart failure, according to the American College of Cardiology 5

Mitral valve repair is strongly preferred over replacement when technically feasible, as recommended by the American College of Cardiology 4, 1
Different surgical techniques are recommended based on specific MVP pathology, including nonresection techniques using PTFE neochord reconstruction or chordal transfer for focal leaflet flail or bileaflet prolapse, focal triangular resection with annuloplasty ring for focal leaflet flail, and sliding leaflet valvuloplasty with annuloplasty ring for diffuse posterior leaflet myxomatous disease, according to the American College of Cardiology 1
Outcomes depend significantly on surgeon experience and center volume, with procedures ideally performed at a Heart Valve Center of Excellence, as recommended by the American Heart Association 4, 1

Endocarditis prophylaxis is recommended for most patients with a definite diagnosis of MVP, particularly if there is associated MR, according to the American Heart Association 5
For patients with MVP and history of stroke, Warfarin therapy is recommended for patients with MR, atrial fibrillation, or left atrial thrombus, and Aspirin therapy is reasonable for patients without MR, atrial fibrillation, left atrial thrombus, or valve thickening, as recommended by the American College of Cardiology 5

Asymptomatic patients with moderate MR should have yearly clinical follow-up with echocardiography every 2 years, as recommended by the American College of Cardiology 1
Asymptomatic patients with severe MR should have clinical evaluation every 6 months with annual echocardiography, according to the American Heart Association 1
Post-repair/replacement, a baseline ECG, X-ray, and echocardiography should be established for future comparison, as recommended by the American College of Cardiology 1